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A B S T R A C T
The aim of this study was to evaluate the laboratory performance of nucleic acid amplification tests
(NATs) for detection of the Mycobacterium tuberculosis complex. A proficiency panel consisting of eight
sputum specimens and four specimens diluted in phosphate-buffered saline (PBS) was sent to 82
laboratories in 23 countries by the Quality Control for Molecular Diagnostics (QCMD) TB programme.
The performance of different NATs was analysed in combination with a questionnaire on the applied
methods. Seventy-eight participants (95.2%) contributed a total of 85 evaluable data sets. The percentage
of correct results on the eight sputum samples was 86.3% (586 ⁄ 679). Of the sputum specimens
considered as ‘smear-negatives’ (650 CFU ⁄ 250 lL), only 61.2% (104 ⁄ 170) were reported positive. The
percentage of correct results for the three scored PBS samples was 75.7% (193 ⁄ 255). The total number of
false-positive results was 11 (4.3%); these were reported for seven (8.2%) of the 85 data sets. In 32
(37.6%) data sets an ‘in-house’ NAT method was used, and in 53 (62.4%) sets a commercial assay was
tested. The percentage of data sets achieving correct results on all sputum samples was 35.3% and
37.8%, respectively. For the PBS samples this was 45.8% and 41.5%. Overall, the results of this study
demonstrated that the performance of NATs for the detection of M. tuberculosis has improved since
previous studies. The percentage of false-positives has decreased considerably. However, a large
number of procedures still lack sufficient sensitivity for application to smear-negative samples.
Keywords Mycobacterium tuberculosis, nucleic acid amplification methods, molecular diagnostics, quality control,
tuberculosis
Original Submission: 24 February 2003; Revised Submission: 6 August 2003; Accepted: 15 August 2003
Clin Microbiol Infect 2004; 10: 295–301
I N T R O D U C T I O N
Nucleic acid amplification tests (NATs) to detect
Mycobacterium tuberculosis in clinical specimens
are used increasingly as a laboratory tool for the
diagnosis of tuberculosis because of their speed,
sensitivity and specificity. There are currently
many commercial and ‘in-house’ NAT methods
available, and these have become an important
addition to the conventional tests in the routine
medical microbiology laboratory. However, pre-
vious external quality control studies have shown
that NATs may be unreliable because of false-
positive results caused by contamination, or
because of false-negative results caused by lack
of sensitivity [1–3]. In the framework of the
Quality Control for Molecular Diagnostics
(QCMD) programme, a proficiency panel distri-
bution was organised to evaluate the laboratory
performance of NATs for detection of the M. tuber-
culosis complex in a panel of sputum samples,
formulated to resemble smear-positive and
smear-negative specimens from infected patients.
The panel also included a serial dilution of
bacteria in saline.
To avoid the high costs associated with ship-
ment of infectious goods on dry ice, the samples
were not prepared with pathogenic human
M. tuberculosis, but with the vaccine strain
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M. bovis BCG, which belongs to the M. tuberculosis
complex and can be detected with all known
NATs for M. tuberculosis. In addition, all samples
were heat-inactivated before shipment.
M A T E R I A L S A N D M E T H O D S
Preparation of sputum pools
Two pools of sputum specimens were prepared, each
c. 400 mL. Pool A comprised a lung aspirate derived from
one patient; Pool B comprised sputum pooled from three
patients. The sputum samples were shaken vigorously for 4 h
in a plastic bottle and frozen at ) 20 C until use. Aliquots of
the sputum pools were analysed by standard methods for
culture and in-house PCR to ensure that they were free from
viable mycobacteria and DNA from the M. tuberculosis com-
plex or other mycobacteria [4–6].
Production of the panel
Samples were prepared at the Public Health Laboratory
Friesland (Leeuwarden, The Netherlands). A liquid culture
of M. bovis BCG was harvested in the logarithmic phase and a
clump-free suspension was prepared as described previously
[2]. In addition to measurement of optical density, viable
counts were determined. Sputum samples from pool A or B
were aliquoted in 250-lL volumes into 1.5-mL screw cap tubes.
Negative samples were closed immediately and 10 lL of
dilutions of M. bovis BCG were added to prepare positive
samples. Phosphate-buffered saline (PBS) samples were pre-
pared by adding dilutions of M. bovis BCG to 1 mL PBS.
Samples were kept at ) 80 C; before shipment the samples
were thawed and heat-inactivated at 80 C for 20 min.
The final panel consisted of eight heat-inactivated sputum
specimens and four heat-inactivated specimens diluted in PBS
(Table 1). Among the sputum samples there were two negative
samples, two strong positive samples containing 50 000
CFU ⁄ 250 lL, two samples with 6500 CFU ⁄ 250 lL, and two
with 650 CFU ⁄ 250 lL. Among the PBS samples there was one
negative sample, one sample with 1000 CFU ⁄mL, one with 100
CFU ⁄mL and one with 10 CFU ⁄mL.
After quality control (QC) examinations at the reference
laboratories, the samples were shipped on dry ice to the
QCMD Central Office in Glasgow, UK. The samples were
randomised in the final panel, as indicated in Table 2, and
sent at ambient temperature to the participants. A package
insert described the testing procedure for the sputum, which
had to be decontaminated and liquefied according to stand-
ard procedures. The PBS samples were considered to resem-
ble the resuspended pellet after the decontamination
procedure and sample preparation. In addition, a panel
receipt form, a results form and a questionnaire were
included in each shipment. To ensure confidentiality, all
participating laboratories received a code number.
Performance scores
The QCMD Neutral Office handled the arrival of reports,
results, questionnaire, coding and confidentiality as described
previously [7]. Data were analysed anonymously in Glasgow
and in Leeuwarden. A simple numerical score was used to
allow comparative analysis of performance. Two points were
assigned for every correct result on a positive or a negative
sample, and no points were assigned for an incorrect result.
One point was assigned for an equivocal result, because in
‘real-life’ such a sample would be repeated and the tubes in the
panel did not contain enough material to repeat the analysis.
The PBS sample with 10 CFU ⁄mL (TB01-12) was not scored.
Scoring and performance assessment was carried out sepa-
rately for the sputum and the PBS samples. The maximum
score was 16 points when all sputum samples were deter-
mined correctly, and six points when the three PBS samples
were determined correctly. Thus a total of 22 points could be
acquired.
R E S U L T S
Validation of detectability of M. tuberculosis
nucleic acids after heat-inactivation
Pilot experiments were performed to test the
influence of heat-inactivation and storage at
ambient temperatures on the detectability of
Table 1. Results from reference test-
ing during pre-distribution quality
control examinations
M. bovis
BCG
CFU
Sample
background
IS6110
in-house
PCRa
Roche Cobas
Amplicor
MTBb
GenProbe
MTDc
Abbott
LCxb
BD
Probe
Tecd
50 000 250 lL sputum A + ⁄+ + + + +
50 000 250 lL sputum B + ⁄+ + + + +
6500 250 lL sputum A + ⁄+ + + + +
6500 250 lL sputum B + ⁄+ + + + +
650 250 lL sputum A + ⁄+ + – + –
650 250 lL sputum B + ⁄+ + – – –
0 250 lL sputum A – ⁄ – – – – –
0 250 lL sputum B – ⁄ – – – – –
1000 1 mL PBS + ⁄+ ⁄+ + – ⁄+ + +
100 1 mL PBS – ⁄+ ⁄ – + + ⁄+ – –
10 1 mL PBS – ⁄ – ⁄ – – + ⁄+ – –
0 1 mL PBS – ⁄ – ⁄ – – – ⁄ – – –
a–dVolume of original sample during amplification:-
a25 lL of sputum sample and 10 lL of PBS sample.
b25 lL.
c6.25 lL of sputum sample and 50 lL of PBS sample.
d26.75 lL of sample.
Where more than one result is shown, these were obtained in separate tests.
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DNA and RNA in M. bovis BCG. Low numbers of
microorganisms, c. 6500, 650 and 0 CFU, were
added to sputum specimens A and B. An aliquot
of these samples was heat-treated at 80 C for
20 min, followed by three cycles of freeze-
thawing. Pilot tests with the IS6110 in-house
PCR and the MTD assay (GenProbe, San Diego,
CA, USA) showed that the treatment had no
influence on the detectability of either mycobac-
terial DNA or RNA in the samples.
Quality control of the final panel
Heat-inactivated samples of the final panel were
sent to the reference laboratories for testing with
the COBAS Amplicor MTB (Roche Diagnostic
Systems, Brandenburg, NJ, USA), GenProbe
MTD, Abbott LCx (Abbott Laboratories, Abbott
Park, IL, USA) and BDProbeTec (Becton Dick-
inson, Sparks, MD, USA) assays. The results are
summarised in Table 1. The IS6110 in-house PCR
was performed on both sputum and PBS panel
samples in duplicate or triplicate to monitor
variability in the series (Table 1). Since the input
of target copies during amplification was as-
sumed to influence the sensitivity of the test, the
percentage of original sample examined in the
NAT was calculated. Sputum samples with 650
CFU ⁄ 250 lL were not positive with all methods,
as was expected, because these samples resem-
bled weak-positive or smear-negative clinical
samples. For the IS6110 in-house PCR, the PBS
sample containing 100 CFU ⁄mL was at the
threshold of detection sensitivity, as the input in
this test was 10 lL (1%) of the original sample,
which corresponds to 1 CFU ⁄PCR. PBS samples
containing 10 CFU ⁄mL were only positive with
the GenProbe MTD test.
Performance of the laboratories
The panel was sent to 82 laboratories in 23 countries
at the end of November 2001. The median transport
time was 1 day, with 55%of panels being delivered
in 1 day and 88% delivered within 7 days. Sev-
enty-one laboratories returned one data set, and
seven returned two data sets, giving a total of
85 assessable data sets. In total, 74 completed
questionnaires were received.
The (highly) positive specimens with 6500 and
50 000 CFU ⁄ 250 lL presented no problems to
most of the participants; > 90% reported correct
results (Table 2). No difference was found
between results from sputum samples A and B.
However, only 69.4% (sputum A) and 52.9%
(sputum B) of results were correct for the weak-
positive sample (650 CFU ⁄ 250 lL), with a signi-
ficant difference in results for sputum A and B
(p < 0.0276). Overall, 586 (86.3%) of the 679 test
results for positive sputum samples were correct
and 20 (5.9%) samples were reported as ‘equivo-
cal requiring repeat testing’. Eight (4.7%) false-
positive results were obtained from the 170
negative sputum samples.
Positive results were obtained for only 20
(23.5%) of the 85 data sets for sample TB12,
containing 10 CFU ⁄mL of PBS. The results for this
sample were not included in the final scores.
An overview of the number of data sets with
the scores for correct results is presented in
Table 3. For the sputum samples TB01–08, a
maximum score of 16 points was achieved for
30 (35.3%) of the 85 data sets. A maximum score
of six was achieved for 39 (45.9%) of the data sets
for the PBS samples TB09–11. A total score of 22
points (100%) for both sputum and PBS samples
was achieved for nine (10.6%) of the 85 data sets.
Table 2. Number of correct results/
sample in 85 data sets
Sample
code
M. bovis
BCG
CFU ⁄ sample
Sample
background
No. of
samples
tested
No. of
positive
results
No. of
negative
results
No. of
equivocal
results
Percentage of
correct
results
TB01-04 50 000 250 lL sputum A 85 84 0 1 98.8
TB01-01 50 000 250 lL sputum B 85 83 1 1 97.7
TB01-07 6500 250 lL sputum A 84 77 4 3 91.7
TB01-06 6500 250 lL sputum B 85 81 1 3 95.3
TB01-02 650 250 lL sputum A 85 59 18 8 69.4
TB01-08 650 250 lL sputum B 85 45 36 4 52.9
TB01-05 0 250 lL sputum A 85 4 78 3 91.8
TB01-03 0 250 lL sputum B 85 4 79 2 92.9
TB01-11 1000 1 mL PBS 85 70 12 3 82.4
TB01-9 100 1 mL PBS 85 44 38 3 51.8
TB01-12a 10 1 mL PBS 85 20 59 6 23.5
TB01-10 0 1 mL PBS 85 3 79 3 92.9
aSample TB01-12 was not scored.
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Comparison of methods
There was a large variation in the types of NATs
used by the participants (Table 3).
Commercial assays were used in 53 (62.4%)
data sets and included: Roche COBAS Amplicor
(n ¼ 22; 41.5%); the ‘manual’ Roche Amplicor
(n ¼ 6; 11.3%); Abbott LCx (n ¼ 3; 5.7%); Gen-
Probe MTD (n ¼ 17; 32.1%); and BD ProbeTec
assay (n ¼ 5; 9.4%).
The scores of the laboratories using the various
assays are shown in Table 3. However, the sample
sizes for each assay and the magnitude of the
differences were too small to draw statistically
significant conclusions on the difference in per-
formance between the assays.
An ‘in-house’ PCR method was used for 32
data sets, including commercial kits not contain-
ing all reagents, such as enzymes for amplifica-
tion. For 11 (34.4%) of these, a single PCR and gel
analysis was used, for five (15.5%) a single PCR
and subsequent hybridisation, for two (6.3%) a
semi-nested PCR, and for six (18.8%) a nested
PCR. A real-time PCR was reported for seven
(21.9%) data sets, including one laboratory using
a semi-nested PCR with real-time detection. One
laboratory did not indicate the type of in-house
method employed. The IS6110 sequence was the
amplification target used by 20 (62.5%) of the
participants employing an ‘in-house’ method. The
16S rRNA gene was targeted for two (6.3%) data
sets, and another two targeted the 65-kDa gene.
Other sequences were targeted for four (12.5%)
sets, and for four data sets no answer was
received. There was no correlation between score
and target gene.
Contamination
Eleven (4.3%) false-positives were generated from
255 examinations on negative samples. These
false-positives were derived from seven data sets:
one laboratory performing the GenProbe MTD
assay reported all three negatives as false-posit-
ive; two laboratories, one using an in-house PCR
and the other the GenProbe MTD assay, reported
two false-positives; and four laboratories per-
forming an in-house PCR reported one false-
positive each. Two of these latter laboratories
used dUTP + uracil glycosylase to avoid contam-
ination with amplicons from previous reactions.
Pre-treatment, inhibition and sample volume
Forty-eight (62.3%) laboratories tested each sam-
ple for potential inhibition of the amplification
reaction. Ten of these reported inhibition for 11
sputum samples. The input volume used in the
Table 3. Comparison of scores and types of assay
Scorea Number of data sets with commercial assays Number of data sets with in-house assays
On
sputum
samples
Total
number
of data
sets (%)
Roche
Amplicor
Cobas
Roche
Amplicor
Abbott
LCx
GenProbe
MTD
BD Probe
Tec
Total
number
commercial
assays
Single
PCR+
gel analysis
Single
PCR+
hybridisation
Semi-
nested
PCR
Real-
time
PCR
Other
method
Total
number
in-house
assays
n ¼ 85 n ¼ 22 n ¼ 6 n ¼ 3 n ¼ 17 n ¼ 5 n ¼ 53 n ¼ 11 n ¼ 5 n ¼ 8 n ¼ 7 n ¼ 1 n ¼ 32
16 30 (35.2) 9 2 3 6 20 1 3 3 3 10
15 3 (3.5) 1 1 1 1 2
14 27 (31.8) 9 3 1 2 15 5 1 2 3 1 12
13 6 (7.1) 2 1 3 6
12 15 (17.6) 1 6 3 10 3 1 1 5
11 1 (1.2) 1 1
10 3 (3.5) 1 1 1 1 2
Mean
score
14.7 14.5 16.0 13.6 12.8 14.2 13.0 15.4 12.9 14.6 14.0 14.0
PBS
samples
6 39 (45.9) 9 1 12 22 2 3 7 5 17
5 1 (1.2) 1 1
4 30 (35.3) 11 4 2 4 2 23 3 1 1 1 1 7
3 2 (2.4) 1 1 1 1
2 12 (14.1) 2 1 1 3 7 4 1 5
1
0 1 (1.2) 1 1
Mean
score
4.6 4.2 3.3 5.3 2.8 4.5 3.5 5.0 5.8 5.1 4.0 4.6
Total 19.3 18.7 19.3 18.9 15.6 18.7 16.5 20.4 18.7 19.7 18.0 18.6
aScoring system as indicated in Materials and Methods.
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amplification reaction ranged from 0.2 to 45% of
the original sample for both sputum and PBS
samples. There was no correlation between input
volume and performance score.
D I S C U S S I O N
The design of this international external quality
control study for the detection of M. tuberculosis
was based on experience from previous studies
[1–3]. The results of the studies in the early and
mid 1990s were rather disappointing. The seven
laboratories participating in the first study in 1993
and 1994 all had experience with development of
NAT methods. However, the results showed that
there was a serious lack of sensitivity and a large
contamination problem. Looking back at the
design of that study, it is now realised that such
a study cannot be considered as a quality per-
formance assessment for routine application of
NATs. At present, it would still be a tremendous
task to investigate 200 samples in a very short
period with in-house PCR procedures.
In the 1996 study, 30 experienced laboratories
each examined a panel of 20 samples. Only five
participants reported correct results, and eight
participants had 100% specificity, but lacked
sensitivity. Seventeen laboratories had problems
with specificity, and 15 of these also had problems
with sensitivity. The results from these studies
were taken to suggest that application of NATs
for the diagnosis of infections with M. tuberculosis
was not useful and should not be performed,
especially in a routine laboratory setting [8]. In
that period, similarly disappointing results were
obtained in studies assessing the performance of
molecular detection of hepatitis B virus DNA and
hepatitis C virus RNA [9,10].
More recent proficiency testing, however, indi-
cated that the performance of laboratories in the
use of NATs for the detection and quantitation of
various infectious agents has improved greatly
[7,11–13]. Further, in contrast to the previous
studies, NATs for detection of the M. tuberculosis
complex are now available from commercial
manufacturers and have become a routine feature
of the clinical microbiology laboratory.
The present study was organised to assess the
quality of the various in-house NATs as well as
the commercial assays for detection of M. tuber-
culosis, and the panel was composed of respirat-
ory samples resembling clinical samples. For the
detection of mycobacteria in sputum by either
culture or NAT, special pre-treatment procedures
are required in order to decontaminate and
liquefy the specimen to allow concentration of
mycobacteria by centrifugation [14]. After resus-
pension of the pellet, the cells can be lysed to
extract nucleic acids for NAT amplification and
subsequent detection. Based on the previous
studies it was acknowledged that these pre-
treatment procedures might introduce false-neg-
ative results through loss of pellets, or false-
positive results caused by contamination between
samples. Furthermore, various NAT procedures
can be influenced differently by ‘carry-through’ of
residual clinical material leading to inhibition of
the amplification reaction, which is a particular
problem with these respiratory specimens. Sam-
ples diluted in PBS were included in the panel to
investigate the sensitivity and specificity of the
amplification reactions in the absence of pre-
treatment steps or inhibition from residual com-
ponents.
Sputum samples containing 50 000 bacteria
were included because very strong positives can
be found in clinical practice and might be a source
of contamination between samples in a run.
However, for the 11 false-positive results reported
in this study, the source of the contamination or
non-specificity was unknown (Table 2).
Samples with 6500 CFU ⁄ 250 lL could be con-
sidered representative of smear-positive samples.
During pre-distribution quality control examina-
tions, these samples were reported positive with
all methods (Table 1). However, of the 169 panel
samples of this type examined by the participants,
only 93.4% were reported correctly. It was not
possible to identify a reason for these false-
negatives from the answers in the questionnaire.
The sensitivity of microscopy for the detection
of acid-fast bacilli on smears is c. 10 000 bac-
teria ⁄mL, and therefore the samples with 650
CFU ⁄ 250 lL were considered smear-negatives.
However, these smear-negatives were not always
reported as positive. In the GenProbe MTD assay,
the volume of sample input is less than that for
the in-house PCR or the COBAS Amplicor assay,
which may have resulted in reduced sensitivity
(Table 1). However, ten of the 17 participants in
the study applying the GenProbe MTD assay did
report correctly one or both smear-negative sam-
ples as positive. Residues from the clinical mater-
ial may cause inhibition of the amplification
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reaction, and the GenProbe MTD and Abbott LCx
assays do not monitor the samples for inhibition.
Samples TB01-02 and TB01-08 were given correct
results in 69.4% and 52.9% of cases, respectively.
Sample TB01-08 contained sputum B, which was
very viscous and dark-coloured. Residues from
this specimen might have caused amplification
inhibition, in contrast to sputum A, which was
more fluid and clear.
The GenProbe MTD assay was able to detect
low numbers of bacteria in the PBS samples as it
targets a multicopy gene (rRNA), thus improving
the sensitivity, although this was evident only
with the clean PBS samples and not in the sputum
samples. The other procedures used a target gene
that is present only as a single copy in the M. bovis
BCG strain provided in the panel. In ‘real life’, the
procedures using IS6110 as a target (in-house
PCR, BD ProbeTec) have the benefit of multiple
copies in most M. tuberculosis strains infecting
humans.
Overall, the results of the present study were an
improvement compared to previous studies on
the performance of NATs for the detection of
M. tuberculosis. Methods have improved and
nowadays many more laboratories are using
commercial tests, i.e., 62.4% vs. 26.7% in 1996
[3]. The commercial tests have quality-controlled
reagents and, theoretically, should be less prone
to contamination than most in-house methods.
The primary purpose of proficiency testing is to
estimate whether a laboratory is capable of
providing reliable results, rather than testing the
performance of different commercial assays. Such
a comparison of different tests is only possible if
each method is used in sufficient numbers; in the
present study, the number of different commer-
cial and in-house assays used did not allow such a
comparison (Table 3). However, it must be noted
that with nearly every method used, there were
one or more data sets with maximum scores, and
data sets with scores regarded as insufficient,
indicating that the results were more user-
dependent than method-specific. In addition,
pre-treatment procedures for decontamination
and liquefaction of sputum specimens are not
provided by the commercial tests, and the local
performance of these procedures will influence
the quality of the test. There was no significant
difference between the mean overall score of the
commercial assays and the in-house assays (18.7
vs. 18.6, respectively).
The increased sensitivity of NATs over conven-
tional assays is usually an important reason to
implement NATs in the routine diagnostic setting.
However, only 61.2% of the data sets reported the
smear-negative samples as positive. This lack of
sensitivity with smear-negative samples has also
been reported by other authors [15–17]. In smear-
positive samples, a NAT improves diagnosis only
by rapid further identification of the mycobacteria
visible by microscopy, i.e., ‘tuberculosis or non-
tuberculosis’, rather than improved sensitivity. In
contrast, when samples are smear-negative, the
bacterial load is too low to be detected by micro-
scopic methods, and a NAT should enhance the
sensitivity of detection and enable rapid identifi-
cation of M. tuberculosis in clinical samples.
Furthermore, a false-positive rate of 4.3% was
reported for the whole panel. Although this was
a considerable improvement over the previous
studies, this rate was still too high. One partici-
pant reported all samples of the QC panel
positive. The three false-positive results in this
particular data set had a large (misleading)
influence on the overall results.
The increasing demand for more rapid and
reliable methods for the diagnosis of tuberculosis
has led to the widespread introduction of molecu-
lar diagnostic procedures into the clinical micro-
biology laboratory. However, in the near future,
NATs will not replace conventional methods such
as microscopy and culture, although the benefits
of the amplification technologies will be increased
sensitivity, specificity and speed of diagnosis. It is
essential that the quality of these methods is
monitored regularly if they are to be introduced
further and accepted in the routine clinical labor-
atory. The QCMD programme aims to improve
the quality of molecular diagnostics for M. tuber-
culosis through the regular distribution of profi-
ciency programmes and QC reference materials. It
also provides a valuable QC information resource
through which clinical laboratories can compare
and contrast their testing procedures with other
laboratories worldwide.
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